NCT03519412 2026-03-03
ARETHUSA
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 2 Completed
Clinical Trials
13 trialsNCT03568188 2026-02-24
FOCALE
Hospices Civils de Lyon
Phase 2 Completed
NCT07293910 2026-02-13
Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection
Tanta University
Phase 2 Recruiting
NCT07406724 2026-02-12
HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma
Qingdao Sino-Cell Biomedicine Co., Ltd.
Phase 2 Not yet recruiting
NCT07336238 2026-02-09
Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies
University of Washington
Phase 2 Not yet recruiting
NCT07339553 2026-01-21
Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Epithelial Ovarian Cancer.
Peking University Third Hospital
Phase 2 Not yet recruiting
NCT07307456 2025-12-29
Tremelimumab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration
Changhai Hospital
Phase 2 Recruiting
NCT07301424 2025-12-24
Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL
University of Alberta
Phase 2 Not yet recruiting
NCT06659705 2025-12-18
INDIGO-FAPI
Institut Curie
Phase 2 Recruiting
NCT06492759 2025-12-16
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
Emory University
Phase 2 Not yet recruiting
NCT07239622 2025-11-20
Liposomal Irinotecan Combined With Sintilimab and Anlotinib in the Treatment of Recurrent or Persistent Ovarian Clear Cell Carcinoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT06057675 2025-08-19
Tranexamic Acid in Nasal Mohs Reconstruction
Vanderbilt University Medical Center
Phase 2 Recruiting
NCT03089554 2025-06-06
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
University of Kentucky
Phase 2 Recruiting